摘要
目的：本研究旨在探讨顺铂联合多西他赛的新辅助化疗在晚期卵巢上皮癌治疗中的作用。方法：2005年1月-2012年7月共98例晚期卵巢上皮癌患者被随机分成新辅助化疗组（48例）和对照组（即非新辅助化疗组，50例）。新辅助化疗组接受顺铂联合多西他赛的新辅助化疗2个周期后，行肿瘤细胞减灭术，术后继续行该方案化疗6个周期：对照组先行肿瘤细胞减灭术，术后行顺铂联合多西他赛化疗6～8个周期。观察两组患者的平均手术时间、术中出血量、理想的肿瘤细胞减灭术成功率以及化疗不良反应和生存情况。结果：新辅助化疗组的平均手术时间和术中出血量均明显少于对照组（P〈0.05），理想的肿瘤细胞减灭术成功率（85.4％）明显高于对照组（48.0％，P〈0.001）。新辅助化疗组中位生存期为39个月，中位无进展生存期为27个月；对照组中位生存期为31个月，中位无进展生存期为20个月（12～27个月）；两组比较的差异均有统计学意义（P均〈0.05）。两组的化疗不良反应相似，差异无统计学意义。结论：顺铂联合多西他赛的新辅助化疗方案治疗晚期卵巢上皮癌患者，可明显降低手术难度，缩短手术时间，减少术中出血量，提高理想的肿瘤细胞减灭术成功率，并改善患者的预后。
Objective： To explore the efficacy and safety of NAC （neoadjuvant chemotherapy） with docetaxel and cisplatin in patients with advanced epithelial ovarian cancer. Methods： Ninety-eight hospitalized patients with advanced ovarian cancer admitted to our hospital between January 2005 and July 2012 were randomly individed into NAC group （n = 48, receiving 2 cycles of NAC with docetaxel and cisplatin followed by cytoreductive surgery and 6 cycles of adjuvant chemotherapy with docetaxel and cisplatin） and the control group （n = 50, receiving cytoreductive surgery and 6-8 cycles of adjuvant chemotherapy with docetaxel and cisplatin）. The mean blood loss, duration of operation and the rate of optimal cytoreductive surgery betweem the two groups were observed and compared. The side effects of chemotherapy and the survival were analyzed. Results： The amount of blood loss and the duration of operation of the NAC group were less than those of the control group （P 〈 0.05）. The rate of optimal cytoreductive surgery of the NAC group was higher than that of the control group （85.4% vs 48.0%, P〈0.001）. The median survival time and the median progression-free survival time were both longer than those of the control group （39 vs 31 months, P〈0.05; 27 vs 20 months, P〈0.05）. The side effects of chemotherapy were not significantly different between the two groups. Conclusion： The NAC regimen with docetaxel and cisplatin can enhance the rate of optimal cytoreductive surgery, reduce the amount of blood loss, shorten the duration of operation, and improve the overall survival of patients with advanced epithelial ovarian cancer.
出处
《肿瘤》
CAS
CSCD
北大核心
2013年第9期827-830,共4页
Tumor
关键词
卵巢肿瘤
新辅助化疗
卵巢上皮癌
顺铂
多西他赛
Ovarian neoplasms
Neoadjuvant chemotherapy
Epithelial ovarian carcinoma
Cisplatin
Docetaxel
